Recent BIOQUANT OSTEO Citations — BIOQUANT

Kristin Reveal

VEGFA from osteoblasts is not required for lamellar bone formation following tibial loading

AUTHORS

Jennifer A. McKenzie, Ian M. Galbreath, Andre F. Coello, Katherine R. Hixon, Matthew J.Silva

ABSTRACT

The relationship between osteogenesis and angiogenesis is complex. Normal bone development requires angiogenesis, mediated by vascular endothelial growth factor A (VEGFA). Studies have demonstrated through systemic inhibition or genetic modification that VEGFA is indispensable for several types of bone repair, presumably via its role in supporting angiogenesis. But a direct role for VEGFA within osteoblasts, in the absence of angiogenesis, has also been suggested. To address the question of whether VEGFA from osteoblasts supports bone formation directly, we applied anabolic loading to induce lamellar bone formation in mice, a process shown to be independent of angiogenesis. We hypothesized that VEGFA from osteoblasts is required for lamellar bone formation. To test this hypothesis, we applied axial tibial compression to inducible Cre/LoxP mice from three lines. Vegfafl/fl mice were crossed with Ubiquitin C (UBC), Osterix (Osx) and Dentin-Matrix Protein 1 (DMP1) Cre-ERT2 mice to target all cells, (pre)osteoblast-lineage cells, and mature osteoblasts and osteocytes, respectively. Genotype effects were determined by comparing control (Vegfafl/fl) and Cre+ (VegfaΔ) mice for each line. At 5 months of age tamoxifen was injected for 5 days followed by a 3-week clearance prior to loading. Female and male mice (N = 100) were loaded for 5 days to peak forces to engender −3100 με peak compressive strain and processed for dynamic histomorphometry (day 12). Percent MS/BS increased 20–70 % as a result of loading, with no effect of genotype in Osx or Dmp1 lines. In contrast, the UBC groups had a significant decrease in relative periosteal BFR/BS in VegfaΔ vs. Vegfafl/fl mice. The UBC line did not have any cortical bone phenotype in non-loaded femurs. In summary, dynamic histomorphometry data confirmed that tibial loading induces lamellar bone formation. Contrary to our hypothesis, there was no decrease in loading-induced bone formation in the Osx or Dmp1 lines in the absence of VEGFA. There was a decrease in bone formation in the UBC line where all cells were targeted. This result indicates that VEGFA from a non-osteoblast cell source supports loading-induced lamellar bone formation, although osteoblast/osteocyte VEGFA is dispensable. These findings support a paracrine model whereby non-osteoblast VEGFA supports lamellar bone formation, independent of angiogenesis.

Constitutive bone marrow adipocytes suppress local bone formation

AUTHORS

Ziru Li, Devika P. Bagchi, Junxiong Zhu, Emily Bowers, Hui Yu, Julie Hardij, Hiroyuki Mori, Katrina Granger, Jon Skjaerlund, Gurjit Mandair, Simin Abrishami, Kanakadurga Singer, Kurt D. Hankenson, Clifford J. Rosen, and Ormond A. MacDougald

ABSTRACT

Bone marrow adipocytes (BMAd) are a unique cell population derived from bone marrow mesenchymal progenitors and marrow adipogenic lineage precursors. Although they have long been considered to be a space-filler within bone cavities, recent studies have revealed important physiological roles in hematopoiesis and bone metabolism. To date, the approaches used to study BMAd function have been confounded by contributions by non-marrow adipocytes or by bone marrow stromal cells. To address this gap in the field, we have developed a BMAdspecific Cre mouse model to deplete BMAds by expression of diphtheria toxin A (DTA), or by deletion of peroxisome proliferator-activated receptor gamma (Pparg). We found that DTAinduced loss of BMAds results in decreased hematopoietic stem and progenitor cell numbers and increased bone mass in BMAd-enriched locations, including the distal tibiae and caudal vertebrae. Elevated bone mass appears to be secondary to enhanced endosteal bone formation, suggesting a local effect caused by depletion of BMAd. Augmented bone formation with BMAd-depletion protects mice from bone loss induced by caloric restriction or ovariectomy,

and facilitates the bone healing process after fracture. Finally, ablation of Pparg also reduces BMAd numbers and largely recapitulates high bone mass phenotypes observed with DTAinduced BMAd depletion.

A novel BMP2 secretagogue ameliorates glucocorticoid induced oxidative stress in osteoblasts by activating NRF2 dependent survival while promoting Wnt/β-catenin mediated osteogenesis

AUTHORS

Divya Rai, Ashish Kumar Tripathi, Anirban Sardar, Alka Raj Pandey, Shradha Sinha, Kunal Chutani, Geeta Dhaniya, Priyanka Kothari, Koneni V. Sashidhara, Ritu Trivedi

ABSTRACT

In our previous study, a novel BMP2 secretagogue was synthesized belonging to a class of galloyl conjugates of flavanones, with remarkable osteogenic potential that promoted bone regeneration. We aimed to establish the protective effect of our compound against bone loss that co-exists with excess Glucocorticoid (GC) therapy. GC therapy induces osteoblast damage leading to apoptosis by increasing reactive oxygen species (ROS). Our results delineate that compound 5e (a BMP2 secretagogue) activates NRF2 signalling to counter the disturbed cellular redox homeostasis and escalate osteoblast survival as assessed by Western blot and immunocytochemistry. Depletion of NRF2 by siRNA blocked activation of the NRF2/HO-1 pathway, magnified oxidative stress, increased apoptosis and abrogated the protective effects of compound 5e. 5e, on the other hand, increased ALP, mineralization activity, and promoted osteoblast differentiation by activating WNT/β-catenin signalling in BMP2 dependent manner, validated by Western blot of WNT3A, SOST, GSK3-β and β-catenin nuclear translocation. Treatment of 5e in presence of BMP inhibitor noggin attenuated the osteogenic efficacy and minimized Wnt//β-catenin signalling in presence of dexamethasone. Our compound prevents GC challenged trabecular and cortical bone loss assessed by micro-CT and promotes bone formation and osteocyte survival determined by calcein labelling and TUNEL assay in GC treated animals. The osteogenic potential of the compound was authenticated by bone turnover markers. On a concluding note, compounds with BMP upregulation can be potential therapeutics for the prevention and treatment of glucocorticoid-induced osteoporosis.

Praeruptorin B inhibits osteoclastogenesis by targeting GSTP1 and impacting on the S-glutathionylation of IKKβ

AUTHORS

Kebin Xu, Ziyi Chen, Jialong Hou, Chenlin Dong, Chengge Shi, Linglin Gao, Zhixian Huang, Ge Shen, Te Wang, Yan Zhou

ABSTRACT

Osteoporosis a common disease in postmenopausal women which contains significant impact on the living quality of women. With the aging of the population, the number of patients suffer from osteoporosis has shown a significant increase. Given the limitations of clinical drugs for the treatment of osteoporosis, natural extracts with small side effects have a great application prospect in the treatment of osteoporosis. Praeruptorin B (Pra-B), is one of the main components found in the roots of Peucedanum praeruptorum Dunn and exhibits anti-inflammatory effects. However, there is no research on the influence of Pra-B on osteoporosis. Here, we showed that Pra-B can dose-dependently suppress osteoclastogenesis without cytotoxicity. Receptor activator of nuclear factor kappa-B (NF-κB) ligand (RANKL)-induced the nuclear import of P65 was inhibited by Pra-B, which indicated the suppressive effect of Pra-B on NF-κB signaling. Further, Pra-B enhanced the expression of Glutathione S-transferase Pi 1 (GSTP1) and promoted the S-glutathionylation of IKKβ to inhibit the nuclear translocation of P65. Moreover, in vivo experiments showed that Pra-B considerably attenuated the bone loss in ovariectomy (OVX)-induced mice. Collectively, our studies revealed that Pra-B suppress the NF-κB signaling targeting GSTP1 to rescued RANKL-induced osteoclastogenesis in vitro and OVX-induced bone loss in vivo, supporting the potential of Pra-B for treating osteoporosis in the future.

Ano5 modulates calcium signaling during bone homeostasis in gnathodiaphyseal dysplasia

AUTHORS

Xin Li, Lei Wang, Hongwei Wang, An Qin & Xingjun Qin

ABSTRACT

ANO5 encodes transmembrane protein 16E (TMEM16E), an intracellular calcium-activated chloride channel in the endoplasmic reticulum. Mutations in ANO5 are associated with gnathodiaphyseal dysplasia (GDD), a skeletal disorder causing the jaw deformity and long bone fractures. However, the coordinated mechanism by which ANO5 mediates bone homeostasis in GDD remains poorly defined. Here, we show that ablation of Ano5 reduced intracellular calcium transients, leading to defects in osteogenesis and osteoclastogenesis and thus bone dysplasia. We found a causative de novo ANO5 frameshift insertion mutation (p.L370_A371insDYWRLNSTCL) in a GDD family with osteopenia, accompanied by a decrease in TMEM16E expression and impaired RANKL-induced intracellular calcium ([Ca2+]i) oscillations in osteoclasts. Moreover, using Ano5 knockout (KO) mice, we found that they exhibited low bone volume, abnormal calcium deposits, and defective osteoblast and osteoclast differentiation. We also showed that Ano5 deletion in mice significantly diminished [Ca2+]i oscillations in both osteoblasts and osteoclasts, which resulted in reduced WNT/β-Catenin and RANKL-NFATc1 signaling, respectively. Osteoanabolic treatment of parathyroid hormone was effective in enhancing bone strength in Ano5 KO mice. Consequently, these data demonstrate that Ano5 positively modulates bone homeostasis via calcium signaling in GDD.

The effect of bone particle size on the histomorphometric and clinical outcomes following lateral ridge augmentation procedures. A randomized double blinded controlled trial

AUTHORS

Hussein S. Basma, Muhammad H.A. Saleh, Nico C. Geurs, Peng Li, Andrea Ravidà, Hom-Lay Wang, Ramzi V. Abou-Arraj

ABSTRACT

Background

The aim of this randomized clinical trial was to clinically and histologically compare the amount and quality of bone gained after lateral ridge augmentation (LRA) procedures performed using small (250-1000μm) versus large (1000-2000μm) particle size cortico-cancellous bone allografts at 6 months following surgical intervention.

Materials and Methods

22 patients, each presenting with ridge width less than 5mm were enrolled. Patients were randomly allocated to small (SP) and large particle (LP) size graft. The gain in ridge width at the level of the crest and 4mm apical to the crest was assessed via a standardized procedure before grafting and at time of implant placement, using a surgical caliper and a novel digital technique using cone beam computed tomography (CBCT). Six months following the procedure, trephine bone cores were taken from 19 augmented sites out of 17 patients (14/19 sites were in the posterior mandible) who completed the study for clinical, histologic and histomorphometric analysis.

Results

17 patients (19 sites) completed the study. LP size graft resulted in greater ridge width gain at the level of the crest (LP, 5.1 ± 1.7; SP, 3.7 ± 1.3 mm; p = 0.0642) and 4mm apical to the crest (LP, 5.9 ± 2.2; SP, 5.1 ± 1.8 mm; p = 0.4480) compared with the SP. No statistical significance for the bone density at the time of implant placement (p = 1.00) was found. Vital bone formation was more extensive in the SP compared with the LP 41.0 ± 10.1% vs 31.4 ± 14.8%, respectively (p = 0.05).

Conclusion

The results of the present article show a trend of higher ridge gain using LP during bone augmentation procedure. Future research with bigger sample size should confirm the results of the present article.